2 results
Approved WMOCompleted
Primary Objective• To compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the progression-free survival (PFS), with that of single-agent cytotoxic chemotherapy in patients with EGFR mutated,…
Approved WMOCompleted
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.